1158 related articles for article (PubMed ID: 21512140)
21. Novel candidate targets of Wnt/beta-catenin signaling in hepatoma cells.
Lee HS; Park MH; Yang SJ; Park KC; Kim NS; Kim YS; Kim DI; Yoo HS; Choi EJ; Yeom YI
Life Sci; 2007 Jan; 80(7):690-8. PubMed ID: 17157329
[TBL] [Abstract][Full Text] [Related]
22. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.
Yamashita T; Budhu A; Forgues M; Wang XW
Cancer Res; 2007 Nov; 67(22):10831-9. PubMed ID: 18006828
[TBL] [Abstract][Full Text] [Related]
23. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
[TBL] [Abstract][Full Text] [Related]
24. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
[TBL] [Abstract][Full Text] [Related]
25. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.
Renard CA; Labalette C; Armengol C; Cougot D; Wei Y; Cairo S; Pineau P; Neuveut C; de Reyniès A; Dejean A; Perret C; Buendia MA
Cancer Res; 2007 Feb; 67(3):901-10. PubMed ID: 17283120
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
27. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation.
Jiang N; Chen WJ; Zhang JW; Xu C; Zeng XC; Zhang T; Li Y; Wang GY
Oncotarget; 2015 Apr; 6(10):7866-79. PubMed ID: 25797263
[TBL] [Abstract][Full Text] [Related]
29. Repression of WT1-Mediated LEF1 Transcription by Mangiferin Governs β-Catenin-Independent Wnt Signalling Inactivation in Hepatocellular Carcinoma.
Tan HY; Wang N; Li S; Hong M; Guo W; Man K; Cheng CS; Chen Z; Feng Y
Cell Physiol Biochem; 2018; 47(5):1819-1834. PubMed ID: 29953980
[TBL] [Abstract][Full Text] [Related]
30. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
31. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
32. Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma.
Huang D; Wang X; Zhuang C; Shi W; Liu M; Tu Q; Zhang D; Hu L
Oncol Rep; 2016 Feb; 35(2):1083-90. PubMed ID: 26718325
[TBL] [Abstract][Full Text] [Related]
33. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2.
Fan H; Zhang H; Pascuzzi PE; Andrisani O
Oncogene; 2016 Feb; 35(6):715-26. PubMed ID: 25893293
[TBL] [Abstract][Full Text] [Related]
35. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.
Chen Y; Lin MC; Yao H; Wang H; Zhang AQ; Yu J; Hui CK; Lau GK; He ML; Sung J; Kung HF
Hepatology; 2007 Jul; 46(1):200-8. PubMed ID: 17596871
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma.
Zhang X; Zhang X; Wang T; Wang L; Tan Z; Wei W; Yan B; Zhao J; Wu K; Yang A; Zhang R; Jia L
Cancer Lett; 2018 Jul; 426():98-108. PubMed ID: 29653269
[TBL] [Abstract][Full Text] [Related]
37. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
Wei W; Chua MS; Grepper S; So S
Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
[TBL] [Abstract][Full Text] [Related]
38. Tumor-suppressive miR-145 co-repressed by TCF4-β-catenin and PRC2 complexes forms double-negative regulation loops with its negative regulators in colorectal cancer.
Wang W; Xiao X; Chen X; Huo Y; Xi WJ; Lin ZF; Zhang D; Li YF; Yang F; Wen WH; Yang AG; Wang T
Int J Cancer; 2018 Jan; 142(2):308-321. PubMed ID: 28921929
[TBL] [Abstract][Full Text] [Related]
39. CARF activates beta-catenin/TCF signaling in the hepatocellular carcinoma.
Fan X; Ma X; Cui L; Dang S; Qu J; Zhang J; Wang X; Mao Z
Oncotarget; 2016 Dec; 7(49):80404-80414. PubMed ID: 27829235
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets.
Kavak E; Najafov A; Ozturk N; Seker T; Cavusoglu K; Aslan T; Duru AD; Saygili T; Hoxhaj G; Hiz MC; Unal DO; Birgül-Iyison N; Ozturk M; Koman A
Cell Signal; 2010 Oct; 22(10):1523-35. PubMed ID: 20538055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
